MY122588A - Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide - Google Patents

Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide

Info

Publication number
MY122588A
MY122588A MYPI20001609A MYPI20001609A MY122588A MY 122588 A MY122588 A MY 122588A MY PI20001609 A MYPI20001609 A MY PI20001609A MY PI20001609 A MYPI20001609 A MY PI20001609A MY 122588 A MY122588 A MY 122588A
Authority
MY
Malaysia
Prior art keywords
methoxy
methylaminothiocarbonylaminosulfonylphenyl
benzamide
chloro
ethyl
Prior art date
Application number
MYPI20001609A
Other languages
English (en)
Inventor
Heinrich Christian Dr Englert
Uwe Dr Gerlach
Harald Dipl Ing Schneider
Tobias Dr Metzenthin
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MY122588A publication Critical patent/MY122588A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C07C335/42—Sulfonylthioureas; Sulfonylisothioureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI20001609A 1999-04-16 2000-04-14 Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide MY122588A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19917233A DE19917233A1 (de) 1999-04-16 1999-04-16 Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids

Publications (1)

Publication Number Publication Date
MY122588A true MY122588A (en) 2006-04-29

Family

ID=7904803

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20001609A MY122588A (en) 1999-04-16 2000-04-14 Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide

Country Status (33)

Country Link
US (1) US6723751B1 (et)
EP (2) EP1173418B1 (et)
JP (1) JP4662640B2 (et)
KR (1) KR100700302B1 (et)
CN (1) CN1168712C (et)
AR (1) AR023479A1 (et)
AT (2) ATE414059T1 (et)
AU (1) AU773246B2 (et)
BR (1) BR0010658A (et)
CA (1) CA2370388C (et)
CZ (1) CZ302459B6 (et)
DE (3) DE19917233A1 (et)
DK (1) DK1173418T3 (et)
EE (1) EE04612B1 (et)
ES (1) ES2251996T3 (et)
HK (1) HK1046270B (et)
HR (1) HRP20010744B1 (et)
HU (1) HU229082B1 (et)
IL (2) IL145921A0 (et)
ME (1) MEP55708A (et)
MX (1) MXPA01010275A (et)
MY (1) MY122588A (et)
NO (1) NO327798B1 (et)
NZ (1) NZ514788A (et)
PL (1) PL203809B1 (et)
RS (1) RS50916B (et)
RU (1) RU2235089C2 (et)
SI (1) SI1173418T1 (et)
SK (1) SK287175B6 (et)
TR (2) TR200102993T2 (et)
TW (1) TWI276622B (et)
WO (1) WO2000063167A1 (et)
ZA (1) ZA200108400B (et)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542852A (en) * 2003-03-17 2008-09-26 Japan Tobacco Inc Pharmaceutical compositions of CETP inhibitors
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2098069T3 (es) * 1993-02-23 1997-04-16 Hoechst Ag Bencenosulfonil-ureas y -tioureas sustituidas, procedimiento para su preparacion y su utilizacion como agentes farmaceuticos.
DE19505397A1 (de) * 1995-02-17 1996-08-22 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU762832B2 (en) * 1998-09-10 2003-07-03 Sanofi-Aventis Deutschland Gmbh Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers

Also Published As

Publication number Publication date
AU773246B2 (en) 2004-05-20
MEP55708A (en) 2011-05-10
CZ302459B6 (cs) 2011-06-01
EP1637519A1 (en) 2006-03-22
HK1046270B (zh) 2005-03-11
EE04612B1 (et) 2006-04-17
PL351245A1 (en) 2003-04-07
SI1173418T1 (sl) 2006-02-28
RS50916B (sr) 2010-08-31
DE19917233A1 (de) 2000-10-19
PL203809B1 (pl) 2009-11-30
DE60024431D1 (en) 2006-01-05
JP2002542230A (ja) 2002-12-10
ZA200108400B (en) 2003-04-30
HUP0200791A3 (en) 2005-04-28
JP4662640B2 (ja) 2011-03-30
AU4542800A (en) 2000-11-02
HRP20010744B1 (en) 2010-08-31
NO20015014L (no) 2001-10-15
ES2251996T3 (es) 2006-05-16
EP1637519B1 (en) 2008-11-12
SK14582001A3 (sk) 2002-01-07
CA2370388A1 (en) 2000-10-26
DE60024431T2 (de) 2006-07-27
MXPA01010275A (es) 2003-07-21
TR200501142T2 (tr) 2005-08-22
ATE414059T1 (de) 2008-11-15
HK1046270A1 (en) 2003-01-03
NZ514788A (en) 2003-03-28
HUP0200791A2 (hu) 2002-07-29
ATE311364T1 (de) 2005-12-15
US6723751B1 (en) 2004-04-20
SK287175B6 (sk) 2010-02-08
AR023479A1 (es) 2002-09-04
WO2000063167A1 (en) 2000-10-26
HRP20010744A2 (en) 2003-04-30
TWI276622B (en) 2007-03-21
KR100700302B1 (ko) 2007-03-29
CN1354744A (zh) 2002-06-19
IL145921A0 (en) 2002-07-25
KR20010109355A (ko) 2001-12-08
RU2235089C2 (ru) 2004-08-27
CN1168712C (zh) 2004-09-29
EP1173418A1 (en) 2002-01-23
IL145921A (en) 2006-07-05
DK1173418T3 (da) 2006-04-10
BR0010658A (pt) 2002-02-19
CA2370388C (en) 2009-10-13
CZ20013672A3 (cs) 2002-01-16
NO20015014D0 (no) 2001-10-15
TR200102993T2 (tr) 2002-03-21
NO327798B1 (no) 2009-09-28
DE60040811D1 (de) 2008-12-24
YU72001A (sh) 2004-07-15
HU229082B1 (hu) 2013-07-29
EP1173418B1 (en) 2005-11-30
EE200100532A (et) 2002-12-16

Similar Documents

Publication Publication Date Title
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HUP0104060A3 (en) Benzamide derivatives and their use as cytokine inhibitors, process for their preparation and medicaments containing them
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2002365516A1 (en) Benzamide derivatives, processes for their preparation, and their pharmaceutical use
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
ZA991572B (en) New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide.
SE0102440D0 (sv) New compound
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
HUP0300972A2 (hu) Gatifloxacin-pentahidrát
ATE253359T1 (de) Antithrombotische mittel
MY120237A (en) Method for the synthesis of quinoline derivatives
HUP0300295A3 (en) Substituted benzamide derivatives, pharmaceutical compositions containing them and their use
HUP0401773A3 (en) Use of [(2-amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkanacid derivatives for the preparation pharmaceutical compositions usable for treatment of pain
MY122588A (en) Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
HK1041000A1 (en) Novel pyrimidine derivatives and processes for thepreparation thereof.
ATE248163T1 (de) Neuartige, pharmazeutisch aktive verbindung
IL152751A0 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
DE69824410D1 (en) Antithrombosemittel
EP1316547A4 (en) NOVEL N-HYDROXY-2 (S) -METHYL-5-ETHOXYMETHOXY-4 (S) - N- (4-PHENOXYPHENYLCARBONYL) AMINO] PENTANAMIDE CRYSTALS, PROCESS FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE CRYSTALS AS AN ACTIVE SUBSTANCE
ES8506710A1 (es) Procedimiento para la obtencion de teofilin-7-acetato de ambroxol
SE9704835D0 (sv) New compound